AMC to Restructure Debt Following Summer Box-Office Boom
Dow Jones2026/09/21 13:45By Connor Hart
AMC Entertainment reported a jump in attendance in July and August, as blockbuster summer releases such as "Spider-Man: Brand New Day" and Christopher Nolan's "The Odyssey" drove consumers back to the multiplex.
The movie-theater operator on Monday reported estimated attendance of 58.2 million for its two months ended Aug. 31, marking a 36% jump from the year prior. The increase drove revenue 42% higher, with per-person spend from both admissions and concessions rising from last year.
Moviegoers united around blockbusters including "Spider-Man: Brand New Day," which recently became the highest-grossing movie of all time at the domestic box office, having so far earned more than $944.5 million, according to Box Office Mojo. Christopher Nolan's adaptation of "The Odyssey" also broke records, becoming the highest grossing R-rated film of all time, with IMAX extending coveted 70mm screenings through September.
AMC's preliminary report came as the company launched a comprehensive debt refinancing aimed at extending its debt maturities and lowering immediate debt-service burdens.
The Leawood, Kan.-based chain said it is seeking to raise approximately $4 billion in new debt, including a private offering of $2 billion in senior secured notes due 2031, an $850 million first-lien term loan facility, and a $1.12 billion second-lien term loan facility committed by Deutsche Bank AG.
AMC plans to use the proceeds, alongside cash on hand, to repurchase or redeem its 7.5% senior secured notes due in 2029, fully redeem outstanding Muvico notes also due in 2029, and pay off existing credit facilities at both AMC and its European subsidiary, Odeon Cinemas Group, it said in a filing with the Securities and Exchange Commission.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
September 21, 2026 09:45 ET (13:45 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
University of Michigan October Consumer Sentiment Index falls to a five-month low, with the Current Economic Conditions Indicator hitting a historic low
The University of Michigan’s Consumer Sentiment Index for October dropped to 46.3, below the market expectation of 47.6. The component reflecting current economic conditions decreased to 44.7, setting a new historical low, while the expectations component edged up to 47.3, marking its first rebound since July. Consumers’ one-year inflation expectations rose to 4.7%, and five-to-ten-year inflation expectations increased to 3.5%. According to the survey director, consumers from different political parties agree that the economic outlook has weakened compared to the beginning of the year.
WTI holds steady as traders weigh US-Iran tensions and supply risks
Japan: Bond outflows reshape global yields - Commerzbank
BUZZ - JPMorgan gives “overweight” rating to LSD-based therapies, Definium stock rises
Latest Updates, October 9th - ** Definium Therapeutics (DFTX.O) shares rose 7.4% to $36.7 ** If the rally holds, the stock is set for its biggest single-day gain since June ** JPMorgan initiated coverage of the stock with an "Overweight" rating and a target price of $84 ** The bank stated that Definium’s lead candidate drug, DT120 ODT, has the potential to transform the treatment landscape for neuropsychiatric disorders ** Based on current data, the institution considers DT120 ODT (an LSD oral formulation for the treatment of major depressive disorder and generalized anxiety disorder) to be a "de-risked asset" ** The new target price implies a 145.7% upside from the latest closing price ** "While changes in the macro environment may present potential investment risks to the sector, we believe the positives for Definium outweigh the negatives," the bank stated ** A period of "frequent landmark events" is expected ahead, including plans to submit a new drug application to the FDA in the first half of 2027 ** The bank projects that total sales of DT120 orally disintegrating tablets (ODT) will approach $5 billion by 2035 ** Including intraday volatility, the stock has more than doubled in value year-to-date (For the convenience of non-English speakers, Reuters has automated this report’s translation into several other languages. Due to possible errors in automated translation or lack of full context, Reuters does not guarantee the accuracy of the automated translation and provides it solely as a convenience to readers. Reuters accepts no liability for any damage or loss arising from the use of automated translation.)
Crypto prices
More
